Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial
Identifieur interne : 000215 ( Main/Exploration ); précédent : 000214; suivant : 000216Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial
Auteurs : T. Reimer ; A. Stachs ; V. Nekljudova ; S. Loibl ; S. Hartmann ; K. Wolter ; G. Hildebrandt ; B. GerberSource :
- Geburtshilfe und Frauenheilkunde [ 0016-5751 ] ; 2017.
Abstract
Axillary lymph node status remains an important prognostic factor in early breast cancer. It is regarded as an indicator for (neo)adjuvant systemic treatment and postoperative radiotherapy of the regional lymphatics. Commenced in September 2015, the INSEMA trial is investigating whether operative determination of nodal status as part of breast conserving therapy (BCT) for early stage breast cancer (c/iT1–2 c/iN0) can be avoided without reducing oncological safety. After inclusion of 1001 patients there was general acceptance of the complex study design by patients and study doctors so that recruitment for the first randomisation (axillary sentinel lymph node biopsy [SLNB]: yes or no) achieved predicted case numbers. The second randomisation however (SLNB alone versus complete axillary dissection when one or two macrometastases are present at SLNB) recruited fewer cases than expected for the following three reasons: a) the 13 % rate of one or two macrometastases after SLNB in the INSEMA trial collective was lower than expected; b) around 20 % of patients refused the second randomisation; c) there was delayed inclusion of the Austrian study centres, which only recruited for the second randomisation. Lack of knowledge of nodal status when SLNB is avoided represents a new challenge for the postoperative tumour board. In particular decisions on chemotherapy for luminal-like tumours and irradiation of the lymphatics (excluding axilla) must be guided by tumour biological parameters. The INSEMA trial does not provide answers to some important questions, e.g. it remains unclear whether patients without SLNB can be offered partial breast irradiation alone in low-risk situations and whether SLNB can also be avoided in patients with stage T1–2 tumours who have a mastectomy indication.
Url:
DOI: 10.1055/s-0042-122853
PubMed: 28331237
PubMed Central: 5357224
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000053
- to stream Pmc, to step Curation: 000053
- to stream Pmc, to step Checkpoint: 000099
- to stream Ncbi, to step Merge: 008E76
- to stream Ncbi, to step Curation: 008E76
- to stream Ncbi, to step Checkpoint: 008E76
- to stream Main, to step Merge: 000215
- to stream Main, to step Curation: 000215
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial</title><author><name sortKey="Reimer, T" sort="Reimer, T" uniqKey="Reimer T" first="T." last="Reimer">T. Reimer</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Stachs, A" sort="Stachs, A" uniqKey="Stachs A" first="A." last="Stachs">A. Stachs</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Nekljudova, V" sort="Nekljudova, V" uniqKey="Nekljudova V" first="V." last="Nekljudova">V. Nekljudova</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S." last="Loibl">S. Loibl</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Hartmann, S" sort="Hartmann, S" uniqKey="Hartmann S" first="S." last="Hartmann">S. Hartmann</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Wolter, K" sort="Wolter, K" uniqKey="Wolter K" first="K." last="Wolter">K. Wolter</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Hildebrandt, G" sort="Hildebrandt, G" uniqKey="Hildebrandt G" first="G." last="Hildebrandt">G. Hildebrandt</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Gerber, B" sort="Gerber, B" uniqKey="Gerber B" first="B." last="Gerber">B. Gerber</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28331237</idno><idno type="pmc">5357224</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357224</idno><idno type="RBID">PMC:5357224</idno><idno type="doi">10.1055/s-0042-122853</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000053</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000053</idno><idno type="wicri:Area/Pmc/Curation">000053</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000053</idno><idno type="wicri:Area/Pmc/Checkpoint">000099</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000099</idno><idno type="wicri:Area/Ncbi/Merge">008E76</idno><idno type="wicri:Area/Ncbi/Curation">008E76</idno><idno type="wicri:Area/Ncbi/Checkpoint">008E76</idno><idno type="wicri:doubleKey">0016-5751:2017:Reimer T:restricted:axillary:staging</idno><idno type="wicri:Area/Main/Merge">000215</idno><idno type="wicri:Area/Main/Curation">000215</idno><idno type="wicri:Area/Main/Exploration">000215</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial</title><author><name sortKey="Reimer, T" sort="Reimer, T" uniqKey="Reimer T" first="T." last="Reimer">T. Reimer</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Stachs, A" sort="Stachs, A" uniqKey="Stachs A" first="A." last="Stachs">A. Stachs</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Nekljudova, V" sort="Nekljudova, V" uniqKey="Nekljudova V" first="V." last="Nekljudova">V. Nekljudova</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S." last="Loibl">S. Loibl</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Hartmann, S" sort="Hartmann, S" uniqKey="Hartmann S" first="S." last="Hartmann">S. Hartmann</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Wolter, K" sort="Wolter, K" uniqKey="Wolter K" first="K." last="Wolter">K. Wolter</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Hildebrandt, G" sort="Hildebrandt, G" uniqKey="Hildebrandt G" first="G." last="Hildebrandt">G. Hildebrandt</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Gerber, B" sort="Gerber, B" uniqKey="Gerber B" first="B." last="Gerber">B. Gerber</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author></analytic><series><title level="j">Geburtshilfe und Frauenheilkunde</title><idno type="ISSN">0016-5751</idno><idno type="eISSN">1438-8804</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Axillary lymph node status remains an important prognostic factor in early breast cancer. It is regarded as an indicator for (neo)adjuvant systemic treatment and postoperative radiotherapy of the regional lymphatics. Commenced in September 2015, the INSEMA trial is investigating whether operative determination of nodal status as part of breast conserving therapy (BCT) for early stage breast cancer (c/iT1–2 c/iN0) can be avoided without reducing oncological safety. After inclusion of 1001 patients there was general acceptance of the complex study design by patients and study doctors so that recruitment for the first randomisation (axillary sentinel lymph node biopsy [SLNB]: yes or no) achieved predicted case numbers. The second randomisation however (SLNB alone versus complete axillary dissection when one or two macrometastases are present at SLNB) recruited fewer cases than expected for the following three reasons: a) the 13 % rate of one or two macrometastases after SLNB in the INSEMA trial collective was lower than expected; b) around 20 % of patients refused the second randomisation; c) there was delayed inclusion of the Austrian study centres, which only recruited for the second randomisation. Lack of knowledge of nodal status when SLNB is avoided represents a new challenge for the postoperative tumour board. In particular decisions on chemotherapy for luminal-like tumours and irradiation of the lymphatics (excluding axilla) must be guided by tumour biological parameters. The INSEMA trial does not provide answers to some important questions, e.g. it remains unclear whether patients without SLNB can be offered partial breast irradiation alone in low-risk situations and whether SLNB can also be avoided in patients with stage T1–2 tumours who have a mastectomy indication.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Gerber, B" sort="Gerber, B" uniqKey="Gerber B" first="B." last="Gerber">B. Gerber</name><name sortKey="Hartmann, S" sort="Hartmann, S" uniqKey="Hartmann S" first="S." last="Hartmann">S. Hartmann</name><name sortKey="Hildebrandt, G" sort="Hildebrandt, G" uniqKey="Hildebrandt G" first="G." last="Hildebrandt">G. Hildebrandt</name><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S." last="Loibl">S. Loibl</name><name sortKey="Nekljudova, V" sort="Nekljudova, V" uniqKey="Nekljudova V" first="V." last="Nekljudova">V. Nekljudova</name><name sortKey="Reimer, T" sort="Reimer, T" uniqKey="Reimer T" first="T." last="Reimer">T. Reimer</name><name sortKey="Stachs, A" sort="Stachs, A" uniqKey="Stachs A" first="A." last="Stachs">A. Stachs</name><name sortKey="Wolter, K" sort="Wolter, K" uniqKey="Wolter K" first="K." last="Wolter">K. Wolter</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000215 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000215 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5357224
|texte= Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28331237" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |